Effect of Inhaled Hydroxy Gas on Long COVID Symptoms
NCT06159296 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25
Last updated 2023-12-06
Summary
The goal of this clinical trial is to see if several weeks of self-administered, home-based, treatment involving breathing hydroxy gas (a mixture of hydrogen and oxygen) for at least 2 hours a day for 3 weeks, will relieve symptoms in patients suffering from Long COVID. The main question it aims to answer is whether inhaling hydroxy gas might be a useful treatment option to help patients with long COVID cope better and recover quicker from this condition.
Participants will wear a nasal canula (placed in their nostrils) to inhale a gas from a machine that they will be trained to use at home. In one 3-week period, the machine will deliver hydroxy gas (treatment) and in a separate 3-week period the machine will deliver normal air (placebo). The order of the treatment or placebo periods will be randomized and separated by a minimum of 3-weeks during which the participants will not use the machine ('washout' period). Neither the participant nor the investigators will know which 3-week period is the treatment and which is the placebo phase. Participants will visit the laboratory (or be tested at home) at the start and end of each 3-week period.
Testing will involve measuring physical ability (handgrip strength, how far they can walk in 6 minutes, how many times they can stand up and sit down in a minute), breathing problems (how hard they can blow out, how breathless they feel), cognitive ability (how quickly they can mark out a trail based on numbers and letters), and state of mind (mood).
The investigators hypothesize that compared to inhaling placebo, inhaling the hydroxy gas will produce greater improvement in physical ability, relieve breathing problems, and enhance cognitive ability and mood, thereby showing that it can relieve key symptoms of long COVID
Conditions
- Post-Acute COVID-19 Syndrome
Interventions
- DEVICE
-
Hydroxy gas
Hydroxy gas is a combination of hydrogen and oxygen together.
Sponsors & Collaborators
-
Oxford Brookes University
lead OTHER
Principal Investigators
-
Shakeeb H Moosavi, PhD · Oxford Brookes University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-09-25
- Primary Completion
- 2024-05-31
- Completion
- 2024-05-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
Hydrogen-Oxygen Generator With Nebulizer for Adjuvant Treatment of COVID-19 Positive Patients
NCT05539664 ·Status: UNKNOWN ·Phase: NA
-
A Study to Investigate the Safety Tolerability Pharmacokinetics, and Pharmacodynamics of Inhaled and Intravenous GSK2862277 in Healthy Volunteers
NCT01818024 ·Status: COMPLETED ·Phase: PHASE1
-
Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection
NCT04290858 ·Status: WITHDRAWN ·Phase: PHASE2
-
The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection
NCT04312997 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.
NCT04871815 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Safety Study of CTX-100 Inhalation Solution (Formerly ETX-100)
NCT00993707 ·Status: COMPLETED ·Phase: PHASE2
-
COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2
NCT04858451 ·Status: TERMINATED ·Phase: PHASE2
-
Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals
NCT04340349 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Efficacy of Breathox Device Inhalation Therapy in the Treatment of Acute Symptoms Associated With COVID-19 and in the Prevention of the Use of Health Resources
NCT05196581 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis
NCT00930982 ·Status: COMPLETED ·Phase: PHASE2
-
Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients
NCT04409886 ·Status: TERMINATED ·Phase: PHASE4
-
The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
NCT04313023 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1, Safety and Bronchopulmonary PK Study in Healthy Volunteers
NCT03691584 ·Status: COMPLETED ·Phase: PHASE1
-
Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19
NCT04305457 ·Status: TERMINATED ·Phase: PHASE2
-
Safety of Ascending Single and Multiple Doses of Nebulised SoftOx Inhalation Solution in Healthy Subjects
NCT05188638 ·Status: COMPLETED ·Phase: PHASE1
-
Inhaled Nitric Oxide for Preventing Progression in COVID-19
NCT04388683 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis
NCT00769119 ·Status: COMPLETED ·Phase: PHASE2
-
Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa)
NCT06663176 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Clinical Trial to Assess the Efficacy and Safety of Inhaled AQ001S in the Management of Acute COVID-19 Symptoms
NCT05000346 ·Status: TERMINATED ·Phase: PHASE2
-
Sulfureous Water Therapy in Viral Respiratory Diseases
NCT06294756 ·Status: COMPLETED ·Phase: NA
-
Evaluate the Efficacy and Safety of N02RS1 in Patient With Acute Bronchitis
NCT02637310 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Respiratory Tract Infection and/or Acute Bronchitis With Ectoin Inhalation Solution
NCT02632851 ·Status: COMPLETED
-
Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175
NCT05628740 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Feasibility Study of Rejuvenair™ for Treating Chronic Bronchitis Patients
NCT02483637 ·Status: COMPLETED ·Phase: NA
-
A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough
NCT05392192 ·Status: COMPLETED ·Phase: PHASE2